Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Kirsten Grunnet"'
Autor:
Armita Armina Abedi, Kirsten Grunnet, Ib Jarle Christensen, Signe Regner Michaelsen, Aida Muhic, Søren Møller, Benedikte Hasselbalch, Hans Skovgaard Poulsen, Thomas Urup
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundGlioblastoma patients administered standard therapies, comprising maximal surgical resection, radiation therapy with concomitant and adjuvant temozolomide, have a variable prognosis with a median overall survival of 15–16 months and a 2-y
Externí odkaz:
https://doaj.org/article/fd68eefa924d45eca16fee3891f5d342
Autor:
Simone Frandsen, Helle Broholm, Vibeke Andrée Larsen, Kirsten Grunnet, Søren Møller, Hans Skovgaard Poulsen, Signe Regner Michaelsen
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: Gliosarcoma (GS) is a rare histopathologic variant of glioblastoma (GBM) characterized by a biphasic growth pattern consisting of both glial and sarcomatous components. Reports regarding its relative prognosis compared to conventional GBM
Externí odkaz:
https://doaj.org/article/109452b6ab404d229b91608c299a7a33
Autor:
Thomas Urup, Signe Regner Michaelsen, Lars Rønn Olsen, Anders Toft, Ib Jarle Christensen, Kirsten Grunnet, Ole Winther, Helle Broholm, Michael Kosteljanetz, Shohreh Issazadeh-Navikas, Hans Skovgaard Poulsen, Ulrik Lassen
Publikováno v:
Molecular Oncology, Vol 10, Iss 8, Pp 1160-1168 (2016)
Background Bevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study w
Externí odkaz:
https://doaj.org/article/bd720aa45e524484b30672fdd8de1366
Autor:
Vibeke Andrée Larsen, Jane Skjøth-Rasmussen, Sofie Mathilde Jacobsen, Kirsten Grunnet, Asma Bashir, Thomas Urup, Sören Möller, Ian Law, Helle Broholm, Hans Skovgaard Poulsen, Otto M. Henriksen
Publikováno v:
Neuro Oncol
BackgroundDiagnostic accuracy in previous studies of O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in patients with suspected recurrent glioma may be influenced by prolonged dynamic PET acquisitions, heterogeneous populations, different non–stan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1fc5c5cd05117dd8f99438503e84a9e
https://doi.org/10.1093/neuonc/noz166
https://doi.org/10.1093/neuonc/noz166
Autor:
Henrik Roed, Michael Lundemann, S.A. Engelholm, P. Munck af Rosenschöld, Aida Muhic, Kirsten Grunnet, H. Skovgaard Poulsen, Ian Law
Publikováno v:
Radiotherapy and Oncology. 130:149-155
We sought to assess the influence of the clinical introduction of new radiotherapy technologies on glioblastoma patients' outcomes.Newly diagnosed glioblastoma patients treated with 60 Gy and temozolomide (2005-2014) were analyzed. The patients' GTV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70431668113895dfc74f6fa181a2664e
https://doi.org/10.1016/j.radonc.2018.10.003
https://doi.org/10.1016/j.radonc.2018.10.003
Autor:
Hans Skovgaard Poulsen, Kirsten Grunnet, Ulrik Lassen, Vibeke Andrée Larsen, Thomas Urup, Ib Jarle Christensen, Helle Broholm, Michael Kosteljanetz, Babloo Lukram, Signe Regner Michaelsen, Anders Toft
Publikováno v:
Cancer Investigation. 36:165-174
Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f836cdaa566accd6b334c5c1ea86369
https://doi.org/10.1080/07357907.2018.1430818
https://doi.org/10.1080/07357907.2018.1430818
Autor:
Sidsel Højklint Poulsen, Aida Muhic, Kirsten Grunnet, Hans Skovgaard Poulsen, Anders Toft, Jan Nyrop Jakobsen, Thomas Urup, Ib Jarle Christensen, Maria Dinche Johansen
Publikováno v:
Journal of Neuro-Oncology. 137:439-446
The combination of lomustine and bevacizumab is a commonly used salvage treatment for recurrent glioblastoma (GBM). We investigated the toxicity and efficacy of lomustine plus bevacizumab (lom-bev) in a community-based patient cohort and made a compa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f9ebaca107820f620d17ac129287b72
https://doi.org/10.1007/s11060-017-2736-x
https://doi.org/10.1007/s11060-017-2736-x
Autor:
Simone Frandsen, Vibeke Andrée Larsen, Kirsten Grunnet, Søren Møller, Signe Regner Michaelsen, Hans Skovgaard Poulsen, Helle Broholm
Publikováno v:
Neuro Oncol
INTRODUCTION Gliosarcoma (GS) is a rare histopathologic variant of glioblastoma (GBM) characterized by a biphasic growth pattern consisting of both glial and sarcomatous components. Reports regarding its relative prognosis compared to conventional GB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d45dded6edca39d2751a98e986fbbbf1
https://europepmc.org/articles/PMC6847475/
https://europepmc.org/articles/PMC6847475/
Autor:
Ib Jarle Christensen, Thomas Urup, Signe Regner Michaelsen, Hans Skovgaard Poulsen, Ulrik Lassen, Kirsten Grunnet
Publikováno v:
Neuro Oncol
Europe PubMed Central
Europe PubMed Central
Glioblastoma is treated by standard with maximal surgical resection followed by radiation therapy with concomitant and adjuvant temozolomide. Still, median overall survival (OS) for glioblastoma is around 15 months, although the prognosis varies grea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e08652a8773295d51e3303b1dd07093
https://europepmc.org/articles/PMC6847771/
https://europepmc.org/articles/PMC6847771/
Autor:
Kirsten Grunnet, Thomas Urup, Ib Jarle Christensen, Ian Law, Sidsel Højklint Poulsen, Per Munck af Rosenschöld, Vibeke Andrée Larsen, Michael Lundemann Jensen, Hans Skovgaard Poulsen
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
Poulsen, S H, Urup, T, Grunnet, K, Christensen, I J, Larsen, V A, Jensen, M L, Af Rosenschöld, P M, Poulsen, H S & Law, I 2017, ' The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, no. 3, pp. 373-381 . https://doi.org/10.1007/s00259-016-3494-2
Poulsen, S H, Urup, T, Grunnet, K, Christensen, I J, Larsen, V A, Jensen, M L, Af Rosenschöld, P M, Poulsen, H S & Law, I 2017, ' The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, no. 3, pp. 373-381 . https://doi.org/10.1007/s00259-016-3494-2
Background Glioblastoma patients show a great variability in progression free survival (PFS) and overall survival (OS). To gain additional pretherapeutic information, we explored the potential of O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET as an indep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e881e7ed6d1463e327e92f6a1c9598
http://europepmc.org/articles/PMC5281673
http://europepmc.org/articles/PMC5281673